Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics
Autor: | Jiri Mayer, Martina Tošková, Barbora Ziakova, Zdenek Racil, Kristina Forsterova, Julia Gabzdilova, Monika Rolencová, Lucia Masárová, Iva Kocmanová, Jan Haber, Petr Cetkovsky, Tomáš Guman, Eva Bojtárová, Lucie Burešová, Shira Timilsina, Michal Kouba, Elena Tóthová, Lubos Drgona |
---|---|
Rok vydání: | 2012 |
Předmět: |
Antifungal
Adult Male Cancer Research Posaconazole medicine.medical_specialty Slovakia Antifungal Agents Neutropenia Fever medicine.drug_class Antineoplastic Agents 03 medical and health sciences Echinocandins Lipopeptides Young Adult 0302 clinical medicine Internal medicine medicine Humans 030212 general & internal medicine Adverse effect Aged Czech Republic Retrospective Studies 0303 health sciences 030306 microbiology business.industry Micafungin Hematology Middle Aged medicine.disease 3. Good health Surgery Fungal disease Treatment Outcome Oncology Multicenter study Hematologic Neoplasms Female business Febrile neutropenia medicine.drug |
Zdroj: | Leukemialymphoma. 54(5) |
ISSN: | 1029-2403 |
Popis: | The objective of this retrospective, multicenter study was to evaluate the efficacy and safety of micafungin as empirical antifungal therapy during febrile neutropenia (FN) in 73 hematological patients from six centers in two countries. All patients received 100 mg of micafungin/day. The overall favorable response rate (RR) was 64.8% when the resolution of fever during neutropenia was included in the response criteria and 84.5% when excluded. A significantly lower favorable RR in patients with persistent fever and non-specific pulmonary infiltrates compared to patients with persistent fever only (82.8 vs. 52.4%, respectively; p = 0.011) was not found when resolution of fever was not included in the composite endpoint criteria (93.1 vs. 78.6%, respectively; p = 0.180). Breakthrough fungal disease developed in 2.7% of patients. Treatment was discontinued in 16.4% of cases. Only one patient (1.4%) discontinued therapy due to an adverse event. Posaconazole prophylaxis improved favorable RR when defervescence was included as composite endpoint criterion (p = 0.047), but not when it was excluded (p = 0.485). However, neutrophil recovery did not influence favorable RR (p = 0.803 and p = 0.112, respectively). These data suggest that micafungin is safe and effective as an empirical therapy in patients with FN. |
Databáze: | OpenAIRE |
Externí odkaz: |